Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma

被引:45
作者
Kitamura, Hiroshi
Honma, Ichiya
Torigoe, Toshihiko
Asanuma, Hiroko
Sato, Noriyuki
Tsukamoto, Taiji
机构
[1] Sapporo Med Univ, Sch Med, Dept Urol, Chuo Ku, Sapporo, Hokkaido 0608543, Japan
[2] Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido 0608543, Japan
基金
日本学术振兴会;
关键词
carcinoma; renal cell; histocompatibility antigens class I; prognosis; survival;
D O I
10.1016/j.juro.2006.11.082
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We determined the prognostic impact of human leukocyte antigen class I on the survival of patients with clear cell renal cell carcinoma. Materials and Methods: Immunohistochemical staining for HLA class I was performed on specimens from 45 patients with clear cell renal cell carcinoma. We performed univariate and multivariate analyses of various factors affecting cause specific survival including HLA class I, Fuhrman grade, TNM stage and tumor size. Furthermore, we compared the survival of patients with HLA class I positive renal cell carcinoma to that of those with down-regulated HLA class I using the Kaplan-Meier method and log rank test. Results: HLA class I was immunohistochemically down-regulated in 17 (37.8%) clear cell renal cell carcinomas. The down-regulation had no correlation with other clinicopathological parameters such as tumor size, perirenal fat invasion, tumor thrombus, TNM stage or nuclear grade. Univariate and multivariate analyses revealed that HLA class I expression, tumor grade and TNM stage were significant factors influencing the disease specific survival of patients with renal cell carcinoma. Patients with HLA class I positive renal cell carcinoma had longer recurrence-free survival than those with down-regulated expression at 5-year followup (95.5% and 61.1%, respectively). Conclusions: Our data demonstrate that down-regulation of HLA class I on tumor cells is an independent prognostic factor for clear cell renal cell carcinoma. This finding suggests that HLA class I restricted cytotoxic T lymphocytes have an important role in the suppression of renal cell carcinoma.
引用
收藏
页码:1269 / 1272
页数:4
相关论文
共 16 条
[1]   Down-regulation of HLA class I antigen processing molecules:: An immune escape mechanism of renal cell carcinoma? [J].
Atkins, D ;
Ferrone, S ;
Schmahl, GE ;
Störkel, S ;
Seliger, B .
JOURNAL OF UROLOGY, 2004, 171 (02) :885-889
[2]   Quantifying viable virus-specific T cells without a priori knowledge of fine epitope specificity [J].
Beadling, Carol ;
Slifka, Mark K. .
NATURE MEDICINE, 2006, 12 (10) :1208-1212
[3]  
Brasanac D, 1999, J EXP CLIN CANC RES, V18, P505
[4]   Natural selection of tumor variants in the generation of "tumor escape" phenotypes [J].
Khong, HT ;
Restifo, NP .
NATURE IMMUNOLOGY, 2002, 3 (11) :999-1005
[5]   Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: Implications for specific immunotherapy [J].
Kitamura, Hiroshi ;
Torigoe, Toshihiko ;
Honma, Ichiya ;
Asanuma, Hiroko ;
Nakazawa, Emiri ;
Shiniozawa, Kumiko ;
Hirohashi, Yoshihiko ;
Sato, Eiji ;
Sato, Noriyuki ;
Tsukamoto, Taiji .
UROLOGY, 2006, 67 (05) :955-959
[6]   Generation, intracellular transport and loading of peptides associated with MHC class I molecules [J].
Koopmann, JO ;
Hammerling, GJ ;
Momburg, F .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (01) :80-88
[7]   Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials [J].
Leibovich, BC ;
Blute, ML ;
Cheville, JC ;
Lohse, CM ;
Frank, I ;
Kwon, ED ;
Weaver, AL ;
Parker, AS ;
Zincke, H .
CANCER, 2003, 97 (07) :1663-1671
[8]   A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma [J].
Lohse, CM ;
Cheville, JC .
CLINICS IN LABORATORY MEDICINE, 2005, 25 (02) :433-+
[9]  
Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6
[10]   Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies [J].
Michael, A ;
Pandha, HS .
LANCET ONCOLOGY, 2003, 4 (04) :215-223